Genetic and Phenotypic Analysis of Multiple Sclerosis in Hispanics
西班牙裔多发性硬化症的遗传和表型分析
基本信息
- 批准号:9490457
- 负责人:
- 金额:$ 62.01万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-08-01 至 2021-11-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAdoptionAffectAllelesAxonCaucasiansCentral Nervous System DiseasesChronicClinicalComplexData AnalysesData SetDeteriorationDevelopmentDiseaseDisease OutcomeDisease susceptibilityEnvironmental ExposureEtiologyEuropeanFamily memberFollow-Up StudiesGenerationsGenesGeneticGenetic Predisposition to DiseaseGenetic VariationGenetic studyGenome ScanGenomicsGenotypeGliosisHLA-DRB1HispanicsImpairmentIndividualInflammationInternationalLightLongevityMeta-AnalysisMethodologyMorbidity - disease rateMultiple SclerosisMyelinNerveNeurodegenerative DisordersNeurologicNeurologic DysfunctionsPathologyPatientsPhenotypePopulationPopulations at RiskPredispositionPrevalenceQuality of lifeReportingResearchRiskRoleScanningSiblingsSusceptibility GeneTechnologyTestingTimeTwin StudiesUnderrepresented PopulationsUnited StatesVariantadmixture mappingclinical heterogeneitycohortcostdisabilityexperiencegene discoverygenetic analysisgenetic associationgenetic variantgenome wide association studygenome-wideimprovedneuroimmunologic diseasenovelracial and ethnicrisk varianttreatment response
项目摘要
PROJECT SUMMARY
This application proposes to address the critical need to include underrepresented populations in genomic
research, with the purpose of enhancing our understanding of the genetic and phenotypic landscape of multiple
sclerosis in the Hispanic population. Multiple sclerosis (MS) is a debilitating neuroimmunological and
neurodegenerative disease of the central nervous system affecting more than 400,000 individuals in the United
States. MS is characterized by chronic inflammation, myelin loss, gliosis, and varying degrees of axonal
pathology which impair saltatory conduction along axons that is necessary for normal functioning of nerve
impulses. MS has an undetermined etiology and results in episodic or progressive neurological dysfunction.
Although life span is modestly shortened, most patients experience increasing disability and consequent
deterioration in quality of life. MS thus carries a significant morbidity that takes an immeasurable toll on the
patients and their family members. The involvement of genetic factors in MS has long been appreciated.
However, the clinical heterogeneity and complex etiology of MS have been confounding factors for genetic
studies. While the first confirmed MS genetic association (with the HLA-DRB1*1501 allele) was identified in the
early 1970's, further gene discoveries were limited until late 2007. At that time, we demonstrated that a common
non-synonymous functional SNP in the IL7RA gene was associated with an increased risk of MS. This result
was confirmed in the first genome-wide association study (GWAS) conducted by the International Multiple
Sclerosis Genetics Consortium (IMSGC). These breakthroughs, along with both statistical and technological
advances, have led to the identification and confirmed association of >190 genetic variants for MS susceptibility.
Despite these advances, we have only uncovered a relatively small proportion of the genetic influences in MS.
Much is yet to be understood regarding the role of these and other genes in MS. We must explore how these
known genetic factors influence not only disease susceptibility, but disease outcomes, therapeutics, and
responses to environmental exposures. While current research findings are unraveling the genetic underpinnings
of individuals with Northern European genetic ancestry, large genetic studies of MS in Hispanics have yet to be
realized. Moreover, the generalization of current findings to individuals of different genetic ancestry is a
significant and unanswered question, especially in light of the reported differences in prevalence, clinical course,
and progression of MS across various ancestral populations. We hypothesize that observed phenotypic
differences between racial/ethnic populations are influenced by population-specific genetic factors. Our proposal
seeks to broaden our understanding of the genetic etiology of multiple sclerosis, with a specific focus on
performing the first battery of comprehensive analyses to elucidate the genetic and phenotypic manifestations
of MS in the diverse Hispanic population, an understudied group that represents a rapidly growing percentage
of the US population. To achieve this, we propose three specific aims: 1) Characterize established MS risk loci
within a Hispanic patient cohort; 2) Perform genome-wide scans to identify novel genetic loci for MS
susceptibility; 3) Explore genotype-phenotype correlations across racial/ethnic populations.
项目概要
该应用旨在解决将代表性不足的人群纳入基因组中的迫切需求
研究,旨在增强我们对多种遗传和表型景观的理解
西班牙裔人口中的硬化症。多发性硬化症 (MS) 是一种使人衰弱的神经免疫学和
中枢神经系统的神经退行性疾病影响了美国超过 400,000 人
国家。 MS 的特点是慢性炎症、髓磷脂缺失、神经胶质增生和不同程度的轴突损伤。
损害沿轴突的跳跃传导的病理学,这是神经正常功能所必需的
冲动。 MS 的病因尚未确定,可导致阵发性或进行性神经功能障碍。
尽管寿命略有缩短,但大多数患者的残疾和随之而来的残疾越来越严重
生活质量恶化。因此,多发性硬化症具有显着的发病率,给患者造成不可估量的损失。
患者及其家人。遗传因素与多发性硬化症的关系早已被人们认识到。
然而,MS 的临床异质性和复杂的病因一直是遗传因素的混杂因素。
研究。虽然第一个确认的 MS 遗传关联(与 HLA-DRB1*1501 等位基因)是在
1970 年代初,进一步的基因发现受到限制,直到 2007 年末。当时,我们证明了一个共同的基因
IL7RA 基因中的非同义功能性 SNP 与 MS 风险增加相关。这个结果
国际多重基因组关联研究(GWAS)证实了这一点
硬化症遗传学联盟 (IMSGC)。这些突破以及统计和技术方面的突破
进展已导致超过 190 个遗传变异与 MS 易感性的关联的鉴定和证实。
尽管取得了这些进展,我们只发现了 MS 中相对较小部分的遗传影响。
关于这些基因和其他基因在多发性硬化症中的作用还有很多待了解。我们必须探索这些
已知的遗传因素不仅影响疾病的易感性,还影响疾病的结果、治疗方法和
对环境暴露的反应。虽然目前的研究结果正在揭示遗传基础
对于具有北欧遗传血统的个体,西班牙裔多发性硬化症的大规模遗传学研究尚未开展
意识到了。此外,将当前的研究结果推广到不同遗传祖先的个体是一个
这是一个重要且尚未解答的问题,特别是考虑到所报告的患病率、临床病程、
以及 MS 在不同祖先人群中的进展。我们假设观察到的表型
种族/族裔人群之间的差异受到人群特定遗传因素的影响。我们的建议
旨在扩大我们对多发性硬化症遗传病因学的理解,特别关注
进行第一组综合分析以阐明遗传和表型表现
多发性硬化症在不同西班牙裔人群中的比例,这是一个未被充分研究的群体,其比例正在快速增长
的美国人口。为了实现这一目标,我们提出了三个具体目标:1) 描述已建立的多发性硬化症风险位点的特征
在西班牙裔患者队列中; 2) 进行全基因组扫描以确定 MS 的新遗传位点
易感性; 3) 探索跨种族/族裔群体的基因型-表型相关性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jacob L McCauley其他文献
Jacob L McCauley的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jacob L McCauley', 18)}}的其他基金
Genetic and Phenotypic Analysis of Multiple Sclerosis in Hispanics
西班牙裔多发性硬化症的遗传和表型分析
- 批准号:
9194041 - 财政年份:2016
- 资助金额:
$ 62.01万 - 项目类别:
Genetic and Phenotypic Analysis of Multiple Sclerosis in Hispanics
西班牙裔多发性硬化症的遗传和表型分析
- 批准号:
9318600 - 财政年份:2016
- 资助金额:
$ 62.01万 - 项目类别:
相似国自然基金
采用积分投影模型解析克隆生长对加拿大一枝黄花种群动态的影响
- 批准号:32301322
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
山丘区农户生计分化对水保措施采用的影响及其调控对策
- 批准号:42377321
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
跨期决策中偏好反转的影响因素及作用机制:采用体验式实验范式的综合研究
- 批准号:72271190
- 批准年份:2022
- 资助金额:43 万元
- 项目类别:面上项目
采用磁共振技术研究帕金森病蓝斑和黑质神经退变及其对大脑结构功能的影响
- 批准号:
- 批准年份:2021
- 资助金额:55 万元
- 项目类别:面上项目
农民合作社视角下组织支持、个人规范对农户化肥农药减量增效技术采用行为的影响机制研究
- 批准号:72103054
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Mental Health and Occupational Functioning in Nurses: An investigation of anxiety sensitivity and factors affecting future use of an mHealth intervention
护士的心理健康和职业功能:焦虑敏感性和影响未来使用移动健康干预措施的因素的调查
- 批准号:
10826673 - 财政年份:2024
- 资助金额:
$ 62.01万 - 项目类别:
Implementation of Innovative Treatment for Moral Injury Syndrome: A Hybrid Type 2 Study
道德伤害综合症创新治疗的实施:2 型混合研究
- 批准号:
10752930 - 财政年份:2024
- 资助金额:
$ 62.01万 - 项目类别:
Leveraging COVID-19 to modernize depression care for VA primary care populations
利用 COVID-19 实现 VA 初级保健人群的抑郁症护理现代化
- 批准号:
10636681 - 财政年份:2023
- 资助金额:
$ 62.01万 - 项目类别:
Efficacy and implementation of exercise-based smoking cessation treatment for adults with high anxiety sensitivity
以运动为基础的戒烟治疗对高焦虑敏感性成人的疗效和实施
- 批准号:
10660767 - 财政年份:2023
- 资助金额:
$ 62.01万 - 项目类别:
Team Support to Improve Glycemic Control Using CGM in Diverse Populations (TEAM CGM)
团队支持在不同人群中使用 CGM 改善血糖控制 (TEAM CGM)
- 批准号:
10659721 - 财政年份:2023
- 资助金额:
$ 62.01万 - 项目类别: